Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Recruiting

Phase 1

OCU-10-C-110Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Sponsor:

Ocugenix Corporation

Code:

NCT05904691

Conditions

Neovascular Age-related Macular Degeneration (nAMD)

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

OCU-10-C-110 for Injection

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-27. This information was provided to ClinicalTrials.gov by Ocugenix Corporation on 2025-03-21.